Recently Sun Pharmaceutical Industries, headquartered in Mumbai, India, announced that the company had received approval from the US Food & Drug Administration for a generic medication used in the treatment of diabetes. The drug, Metformin Hydrochloride extended release tablets, will likely be launched in the coming weeks in America according to news reports.

In a BSE filing, Sun Pharma said that a subsidiary of the company “has received final approval from USFDA for its abbreviated new drug application for generic version of Glumetza Metformin Hydrochloride extended release tablets.” The tablets, which have been approved for dosages of 500 mg and 1,000 mg, are generic versions of Santarus Inc.’s Glumetza tablets, according to the company and are designed to be used in adults with type 2 diabetes, along with diet and exercise, to improve control of blood sugar (glucose) levels.

According to reports, as of June 2016 Santarus Inc.’s Glumetza tablets have sales in the US annually of about $1.2 billion.

At REA JET we understand the right pharma coding and marking solution is vital not only for clear, legible marking of pharmaceutical products, but increased productivity and track & trace capabilities. Our products help ensure precise data can be tracked across the entire supply chain, thereby minimizing the risk of counterfeiting. For all of your pharmaceutical coding and marking needs, trust REA JET to deliver exceptional solutions.